5 million Americans currently live with heart failure, and 670,000 new cases are diagnosed each year. Only 2000 advanced heart failure patients receive transplants each year. More than 250,000 advanced heart failure patients have no viable treatment option  and up to 100,000 of these could benefit from a Left Ventricular Assist Device or LVAD.

Current generation of heart-assist pumps or LVADs are continuous-flow (CF). Nearly every biological system, however, is regulated by ebb and flow of blood. Various biological processes in the human body rely on consistent, pulsatile blood flow to be effective. Research shows CF devices cause problems such as hemolysis, gastrointestinal bleeding, and aortic insufficiency. Continuous blood flow may also lead to reduced blood flow and higher blood pressure, increase in vascular resistance, shown increase in toxins, decrease in platelet counts, low blood oxygen levels, damage to vascular walls and organ beds, and disruption of immune system functions.

One of the founding aims of BRHAMA labs is to produce strong, mathematically accurate pulsed flow (PF) at required frequencies to mimic the human heart, while being compact and reliable. 

Experiments show that a strong pulse can be generated with our technology. The system offers simple and robust control and is very scalable.

Above: Our test fluid circuit, featuring a HeartMate 2 LVAD. The black box is to redact our proprietary technology that produces puslation.